Regulation of xenobiotic receptors PXR and CAR, and CYP3A: implications in drug disposition
外源性受体 PXR 和 CAR 以及 CYP3A 的调节:对药物处置的影响
基本信息
- 批准号:10595631
- 负责人:
- 金额:$ 44.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-04-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:Adverse drug effectAffectBiological AvailabilityCYP3A4 geneCYP3A5 geneCell modelChemicalsComprehensionCytochrome P450DevelopmentDiabetes MellitusDiseaseDrug PrescriptionsDrug resistanceDrug toxicityEnzymesGenetic TranscriptionGoalsHomeostasisHumanLigandsMalignant NeoplasmsNuclear ReceptorsOutcomePharmaceutical PreparationsPharmacotherapyPost-Translational RegulationRegulationRoleTechnologyTherapeuticTissuesToxicologyTreatment EfficacyTreatment FailureXenobiotic MetabolismXenobioticsconstitutive androstane receptordesigndrug dispositiondrug efficacyflexibilityhuman diseaseimprovedin vivoinhibitorinnovationnovelposttranscriptionalpregnane X receptorpreventprotein protein interactionreceptortool
项目摘要
Manipulation of drug disposition offers an avenue toward enhancing drug efficacy and reducing adverse drug
effects (including drug toxicity and drug resistance, the leading causes of drug treatment failure). We study the
regulation of human pregnane X receptor (hPXR), constitutive androstane receptor (hCAR), cytochromes P450
(CYP)3A4 and CYP3A5, along with their roles in drug disposition. hPXR and hCAR are nuclear receptors
modulated by many structurally diverse chemicals. They transcriptionally regulate transporters and drug-
metabolizing enzymes (including CYP3A4 and CYP3A5, which metabolize more than 50% of prescribed drugs)
to control xenobiotic disposition and endobiotic homeostasis, and are implicated in drug effects and in the
development of human diseases (e.g., diabetes and cancer). Several key gaps remain in our understanding of
the regulation of hPXR, hCAR, CYP3A4, and CYP3A5. First, hPXR and hCAR display ligand promiscuity and
structural flexibility, but how compounds affect receptor activities, and how the two receptors co-regulate drug
disposition, remain elusive. An innovative and systematic effort is needed to develop chemical tools to dissect
hPXR and hCAR regulation in detail. Second, how CYP3A4 and CYP3A5 are differentially regulated in a tissue-
and disease-context–dependent manner is unknown. Our two long-term goals are 1) to comprehensively
understand the regulation of hPXR, hCAR, CYP3A4, and CYP3A5 and its implications for drug disposition and
human diseases, and 2) to develop chemical tools to elucidate their regulation, prevent drug toxicity, and improve
drug bioavailability. We have advanced toward these goals by discovering novel mechanisms that regulate
hPXR, hCAR, and CYP3A5 (including transcriptional, post-transcriptional, and post-translational regulation, and
previously unknown protein–protein interactions), and by developing novel compounds that specifically target
them. We will meet 3 challenges during the next five years: (1) The mechanism by which binders of hPXR or
hCAR trigger varying cellular outcomes to differentially affect xenobiotic metabolism is still not well defined,
hindering our ability to accurately assess drug effects. We will develop compounds and assess their mechanisms
of action and in vivo efficacy. (2) The functional relation between hPXR and hCAR and the underlying mechanism
remain unclear, preventing an effective modulating approach. We will fully characterize the relation and develop
compounds to modulate it and xenobiotic metabolism. (3) How CYP3A4 and CYP3A5 are differentially regulated
is unclear. We will develop CYP3A5-specific inhibitors, identify the regulators of CYP3A5 expression, and
develop appropriate cell models and advanced technological approaches to investigate the novel roles of
CYP3A5. Together, our findings will provide a broader comprehension of the regulation of hPXR, hCAR,
CYP3A4, and CYP3A5; define the previously unclear functional relation between hPXR and hCAR and design
paradigm-shifting approaches to modulate it; reveal novel regulation and roles of CYP3A5; and generate novel
chemical compounds as leads for therapies to prevent drug toxicity and improve drug bioavailability.
药物处置的操纵提供了一条提高药物疗效和减少药物不良反应的途径
影响(包括药物毒性和耐药性,药物治疗失败的主要原因)。我们研究
人雄烷X受体(hPXR)、组成型雄烷受体(hCAR)、细胞色素P450的调节
(3)3A 4和CYP 3A 5,沿着及其在药物处置中的作用。hPXR和hCAR是核受体
由许多结构不同的化学物质调节。它们转录调节转运蛋白和药物-
代谢酶(包括CYP 3A 4和CYP 3A 5,代谢超过50%的处方药)
控制异生质处置和内源性体内平衡,并与药物作用和
人类疾病的发展(例如,糖尿病和癌症)。在我们的理解中,
hPXR、hCAR、CYP 3A 4和CYP 3A 5的调节。首先,hPXR和hCAR显示配体混杂,
结构灵活性,但化合物如何影响受体活性,以及两种受体如何共同调节药物
性格,仍然难以捉摸。需要创新和系统的努力来开发化学工具,
hPXR和hCAR调控的详细信息。第二,CYP 3A 4和CYP 3A 5在组织中的差异调节-
和疾病背景依赖的方式是未知的。我们的两个长期目标是:1)全面
了解hPXR、hCAR、CYP 3A 4和CYP 3A 5的调节及其对药物处置的影响,
人类疾病,和2)开发化学工具,以阐明其调节,防止药物毒性,并改善
药物生物利用度我们已经朝着这些目标前进,通过发现新的机制,
hPXR、hCAR和CYP 3A 5(包括转录、转录后和翻译后调控,以及
以前未知的蛋白质-蛋白质相互作用),并通过开发特异性靶向
他们在未来五年内,我们将面临3个挑战:(1)hPXR或
hCAR触发不同的细胞结果以差异地影响异生物质代谢仍然没有很好地定义,
阻碍了我们准确评估药效的能力我们将开发化合物并评估其机制
的作用和体内功效。(2)hPXR与hCAR的功能关系及其机制
仍然不清楚,阻止了有效的调节方法。我们将充分描述这种关系,
化合物来调节它和异生物质代谢。(3)CYP 3A 4和CYP 3A 5如何差异调节
还不清楚我们将开发CYP 3A 5特异性抑制剂,鉴定CYP 3A 5表达的调节剂,并
开发适当的细胞模型和先进的技术方法,以研究新的作用,
CYP3A5。总之,我们的研究结果将提供对hPXR,hCAR,
CYP 3A 4和CYP 3A 5;定义了hPXR和hCAR之间先前不清楚的功能关系以及设计
范式转换方法来调节它;揭示CYP 3A 5的新调节和作用;并产生新的
化合物作为预防药物毒性和提高药物生物利用度的疗法的先导。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Taosheng Chen其他文献
Taosheng Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Taosheng Chen', 18)}}的其他基金
Development of small molecules to target KDM4B
开发针对 KDM4B 的小分子
- 批准号:
9580417 - 财政年份:2018
- 资助金额:
$ 44.88万 - 项目类别:
Development of small molecules to target KDM4B
开发针对 KDM4B 的小分子
- 批准号:
10188460 - 财政年份:2018
- 资助金额:
$ 44.88万 - 项目类别:
Regulation of xenobiotic receptors PXR and CAR: implications in drug disposition
外源性受体 PXR 和 CAR 的调节:对药物处置的影响
- 批准号:
9889965 - 财政年份:2016
- 资助金额:
$ 44.88万 - 项目类别:
Regulation of xenobiotic receptors PXR and CAR, and CYP3A: implications in drug disposition
外源性受体 PXR 和 CAR 以及 CYP3A 的调节:对药物处置的影响
- 批准号:
10391535 - 财政年份:2016
- 资助金额:
$ 44.88万 - 项目类别:
Regulation of xenobiotic receptors PXR and CAR, and CYP3A: implications in drug disposition
外源性受体 PXR 和 CAR 以及 CYP3A 的调节:对药物处置的影响
- 批准号:
10206725 - 财政年份:2016
- 资助金额:
$ 44.88万 - 项目类别:
Regulation of xenobiotic receptors PXR and CAR: implications in drug disposition
外源性受体 PXR 和 CAR 的调节:对药物处置的影响
- 批准号:
9516642 - 财政年份:2016
- 资助金额:
$ 44.88万 - 项目类别:
Regulation of drug disposition by a novel microRNA-mediated pathway
通过新型 microRNA 介导的途径调节药物分布
- 批准号:
9005869 - 财政年份:2014
- 资助金额:
$ 44.88万 - 项目类别:
Regulation of drug disposition by a novel microRNA-mediated pathway
通过新型 microRNA 介导的途径调节药物分布
- 批准号:
8670437 - 财政年份:2014
- 资助金额:
$ 44.88万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 44.88万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 44.88万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 44.88万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 44.88万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 44.88万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 44.88万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 44.88万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 44.88万 - 项目类别:
Studentship